Dermata Therapeutics Inc (DRMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.06M
Last updated: Nov 17, 2026 at 11:01 AM ET
Dermata Therapeutics Inc (DRMA) Earnings: Report Dates and Results
Dermata Therapeutics (DRMA) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Dermata Therapeutics reported EPS of -$0.55. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DRMA has an expected report date of Mar 24, 2027.
Earnings History
Of the 21 quarters below that had an estimate, DRMA beat 15 and missed 6. The widest gap in the table came in the quarter ended Sep 30, 2021, when EPS landed 244.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.55 | -$0.55 | -$0.55 - -$0.55 | N/A | N/A | N/A | 1 | 1 up, 0 down | Nov 10, 2026 |
| Jun 30, 2026 | -$0.74 | -$0.55 | -$0.55 - -$0.55 | -34.55% | Miss | N/A | 1 | 0 up, 1 down | Aug 11, 2026 |
| Mar 31, 2026 | -$0.48 | -$0.53 | -$0.53 - -$0.53 | +9.43% | Beat | N/A | 1 | 1 up, 0 down | May 13, 2026 |
| Dec 31, 2025 | -$1.52 | -$1.54 | -$1.54 - -$1.54 | +1.30% | Beat | N/A | 1 | 0 up, 1 down | Mar 26, 2026 |
| Sep 30, 2025 | -$1.65 | -$1.59 | -$1.59 - -$1.59 | -3.77% | Miss | N/A | 1 | 1 up, 0 down | Nov 14, 2025 |
| Jun 30, 2025 | -$1.66 | -$2.90 | N/A | +42.76% | Beat | N/A | N/A | 0 up, 0 down | Aug 13, 2025 |
| Mar 31, 2025 | -$1.25 | -$0.45 | N/A | -178.11% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2025 |
| Dec 31, 2024 | -$13.40 | -$15.00 | N/A | +10.67% | Beat | N/A | N/A | 0 up, 0 down | Mar 17, 2025 |
| Sep 30, 2024 | -$20.40 | -$26.40 | -$26.40 - -$26.40 | +22.73% | Beat | N/A | 1 | 0 up, 0 down | Nov 13, 2024 |
| Jun 30, 2024 | -$41.80 | -$37.90 | -$37.90 - -$37.90 | -10.29% | Miss | N/A | 1 | 0 up, 0 down | Aug 7, 2024 |
| Mar 31, 2024 | -$4.70 | -$3.60 | N/A | -30.49% | Miss | N/A | 1 | 0 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$0.21 | -$0.78 | N/A | +73.08% | Beat | N/A | N/A | 0 up, 0 down | Mar 21, 2024 |
| Sep 30, 2023 | -$81.00 | -$94.50 | N/A | +14.29% | Beat | N/A | 1 | 0 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$94.50 | -$138.00 | N/A | +31.52% | Beat | N/A | 1 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$340.50 | -$397.50 | N/A | +14.34% | Beat | N/A | 1 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$288.00 | -$480.00 | N/A | +40.00% | Beat | N/A | 1 | 0 up, 0 down | Feb 21, 2023 |
| Sep 30, 2022 | -$480.00 | -$528.00 | N/A | +9.09% | Beat | N/A | 1 | 0 up, 0 down | Nov 10, 2022 |
| Jun 30, 2022 | -$576.00 | -$768.00 | N/A | +25.00% | Beat | N/A | 1 | 0 up, 0 down | Aug 15, 2022 |
| Mar 31, 2022 | -$792.00 | -$960.00 | N/A | +17.50% | Beat | N/A | 1 | 0 up, 0 down | May 16, 2022 |
| Dec 31, 2021 | -$4.16 | -$5.68 | -$6.72 - -$4.64 | +26.76% | Beat | N/A | 2 | 0 up, 0 down | Mar 28, 2022 |
| Sep 30, 2021 | -$2,064.00 | -$600.00 | -$1,655.17 - -$551.72 | -244.00% | Miss | N/A | 2 | N/A | Nov 15, 2021 |
| Jun 30, 2021 | -$11.20 | -$22.56 | N/A | +50.35% | Beat | N/A | N/A | N/A | Aug 16, 2021 |
| Dec 31, 2020 | -$1.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 |
| Dec 31, 2019 | -$0.74 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$6.08, after -$80.30 the year before. It was -$0.74 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$6.08 | N/A |
| Dec 31, 2024 | -$80.30 | N/A |
| Dec 31, 2023 | -$516.21 | N/A |
| Dec 31, 2022 | -$2,136.00 | N/A |
| Dec 31, 2021 | -$2,079.36 | N/A |
| Dec 31, 2020 | -$1.21 | N/A |
| Dec 31, 2019 | -$0.74 | N/A |
Frequently Asked Questions About DRMA
When is Dermata Therapeutics's next earnings date?
Dermata Therapeutics's next earnings report is expected for Mar 24, 2027.
What EPS do analysts expect from DRMA next quarter?
The consensus EPS estimate for Dermata Therapeutics for the quarter ending Dec 31, 2026 is -$0.47 from 3 analysts.
How often does DRMA beat earnings estimates?
Dermata Therapeutics beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of -16.19%.
DRMA pages: Overview, Earnings, Forecast, Financials, Competitors